1. |
Willis J, Morse L, Vitale S, et al. Treatment patterns for myopic choroidal neovascularization in the united states: analysis of the IRIS registry[J]. Ophthalmology, 2017, 124(7): 935-943. DOI: 10.1016/j.ophtha.2017.02.018..
|
2. |
Wong TY, Ohno-Matsui K, Leveziel N, et al. Myopic choroidal neovascularisation: current concepts and update on clinical management[J]. Br J Ophthalmol, 2015, 99(3): 289-296. DOI: 10.1136/bjophthalmol-2014-305131.
|
3. |
Ladaique MDirani A, Ambresin A. Long-term follow-up of choroidal neovascularization in pathological myopia treated with intravitreal ranibizumab[J]. Klin Monbl Augenheilkd, 2015, 232(4): 542-547. DOI: 10.1055/s-0035-1545817.
|
4. |
Neelam K, Cheung CM, Ohno-Matsui K, et al. Choroidal neovascularization in pathological myopia[J]. Prog Retin Eye Res, 2012, 31(5): 495-525. DOI: 10.1016/j.preteyeres.2012.04.001.
|
5. |
Ohno-Matsui K, Yoshida T, Futagami S, et al. Patchy atrophy and lacquer cracks predispose to the development of choroidal neovascularisation in pathological myopia[J]. Br J Ophthalmol, 2003, 87(5): 570-573.
|
6. |
Wakabayashi T, Ikuno Y. Choroidal filling delay in choroidal neovascularisation due to pathological myopia[J]. Br J Ophthalmol, 2010, 94(5): 611-615. DOI: 10.1136/bjo.2009.163535.
|
7. |
Wang S, Wang Y, Gao X, et al. Choroidal thickness and high myopia: a cross-sectional study and meta-analysis[J]. BMC Ophthalmol, 2015, 15: 70. DOI: 10.1186/s12886-015-0059-2.
|
8. |
Chen W, Song H, Xie S, et al. Correlation of macular choroidal thickness with concentrations of aqueous vascular endothelial growth factor in high myopia[J]. Curr Eye Res, 2015, 40(3): 307-313. DOI: 10.3109/02713683.2014.973043.
|
9. |
Harb E, Hyman L, Gwiazda J, et al. Choroidal thickness profiles in myopic eyes of young adults in the correction of myopia evaluation trial cohort[J]. Am J Ophthalmol, 2015, 160(1): 62-71. DOI: 10.1016/j.ajo.2015.04.018.
|
10. |
Rong SS, Chen LJ, Pang CP. Myopia genetics-the asia-pacific perspective[J]. Asia Pac J Ophthalmol (Phila), 2016, 5(4): 236-244. DOI: 10.1097/APO.0000000000000224.
|
11. |
Miyake M, Yamashiro K, Nakanishi H, et al. Evaluation of pigment epithelium-derived factor and complement factor I polymorphisms as a cause of choroidal neovascularization in highly myopic eyes[J]. Invest Ophthalmol Vis Sci, 2013, 54(6): 4208-4212. DOI: 10.1167/iovs.13-12280.
|
12. |
Leveziel N, Yu Y, Reynolds R, et al. Genetic factors for choroidal neovascularization associated with high myopia[J]. Invest Ophthalmol Vis Sci, 2012, 53(8): 5004-5009. DOI: 10.1167/iovs.12-9538.
|
13. |
Brown DM, Michels M, Kaiser PK, et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study[J]. Ophthalmology, 2009, 116(1): 57-65. DOI: 10.1016/j.ophtha.2008.10.018.
|
14. |
Li X, Xu G, Wang Y, et al. Safety and efficacy of conbercept in neovascular age-related macular degeneration: results from a 12-month randomized phase 2 study: AURORA study[J]. Ophthalmology, 2014, 121(9): 1740-1747. DOI: 10.1016/j.ophtha.2014.03.026.
|
15. |
Verteporfin in Photodynamic Therapy (VIP) Study Group.Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin: 1-year results of a randomized clinical trial--VIP report no. 1[J]. Ophthalmology, 2001, 108(5): 841-852. DOI: 10.1016/S0161-6420(01)00544-9.
|
16. |
Blinder KJ, Blumenkranz MS, Bressler NM, et al. Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial--VIP report no. 3[J]. Ophthalmology, 2003, 110(4): 667-673. DOI: 10.1016/S0161-6420(02)01998-X.
|
17. |
Tufail A, Narendran N, Patel PJ, et al. Ranibizumab in myopic choroidal neovascularization: the 12-month results from the REPAIR study[J]. Ophthalmology, 2013, 120(9): 1944-1945. DOI: 10.1016/j.ophtha.2013.06.010.
|
18. |
Wolf S, Balciuniene VJ, Laganovska G, et al. RADIANCE: a randomized controlled study of ranibizumab in patients with choroidal neovascularization secondary to pathologic myopia[J]. Ophthalmology, 2014, 121(3): 682-692. DOI: 10.1016/j.ophtha.2013.10.023.
|
19. |
Mathieu B, Isaico R, Ramel JC, et al. [Treatment of high myopic choroidal neovascularisation with intravitreal bevacizumab][J]. J Fr Ophtalmol, 2014, 37(1): 54-57. DOI: 10.1016/j.jfo.2013.07.006.
|
20. |
Yoshida T, Ohno-Matsui K, Yasuzumi K, et al. Myopic choroidal neovascularization: a 10-year follow-up[J]. Ophthalmology, 2003, 110(7): 1297-1305. DOI: 10.1016/S0161-6420(03)00461-5.
|
21. |
Keane PA, Liakopoulos S, Chang KT, et al. Comparison of the optical coherence tomographic features of choroidal neovascular membranes in pathological myopia versus age-related macular degeneration, using quantitative subanalysis[J]. Br J Ophthalmol, 2008, 92(8): 1081-1085. DOI: 10.1136/bjo.2008.138891.
|
22. |
Querques G, Corvi F, Querques L, et al. Optical coherence tomography angiography of choroidal neovascularization secondary to pathologic myopia[J]. Dev Ophthalmol 2016, 56(: 101-106. DOI: 10.1159/000442800.
|
23. |
Baba T,Ohno-Matsui K, Yoshida T, et al. Optical coherence tomography of choroidal neovascularization in high myopia[J]. Acta Ophthalmol Scand, 2002, 80(1): 82-87.
|
24. |
Chhablani J, Deepa MJ, Tyagi M, et al. Fluorescein angiography and optical coherence tomography in myopic choroidal neovascularization[J]. Eye (Lond) , 2015, 29(4): 519-524, doi: 10.1038/eye.2014.345.
|
25. |
Hampton GR, Kohen D, Bird AC. Visual prognosis of disciform degeneration in myopia[J]. Ophthalmology, 1983, 90(8): 923-926.
|
26. |
Parodi MB, Iacono P, Papayannis A, et al. Laser photocoagulation, photodynamic therapy, and intravitreal bevacizumab for the treatment of juxtafoveal choroidal neovascularization secondary to pathologic myopia[J]. Arch Ophthalmol, 2010, 128(4): 437-442. DOI: 10.1001/archophthalmol.2009.408.
|
27. |
Ruiz-Moreno JM, Lopez-Galvez MI, Donate J, et al. Myopic choroidal neovascularization[J]. Ophthalmology, 2011, 118(12): 2521-2523. DOI: 10.1016/j.ophtha.2011.07.029.
|
28. |
Baba T, Kubota-Taniai M, Kitahashi M, et al. Two-year comparison of photodynamic therapy and intravitreal bevacizumab for treatment of myopic choroidal neovascularisation[J]. Br J Ophthalmol, 2010, 94(7): 864-870. DOI: 10.1136/bjo.2009.166025.
|
29. |
Ikuno Y, Jo Y, Hamasaki T, et al. Ocular risk factors for choroidal neovascularization in pathologic myopia[J]. Invest Ophthalmol Vis Sci, 2010, 51(7): 3721-3725. DOI: 10.1167/iovs.09-3493.
|
30. |
Yoon JU, Byun YJ, Koh HJ. Intravitreal anti-VEGF versus photodynamic therapy with verteporfin for treatment of myopic choroidal neovascularization[J]. Retina, 2010, 30(3): 418-424. DOI: 10.1097/IAE.0b013e3181bd2fe4.
|
31. |
Figurska M, Stankiewicz A.Anty-VEGF therapy in the treatment of myopic macular choroidal neovascularization--cases report[J]. Klin Oczna, 2008;110(10-12): 387-391.
|
32. |
Ruiz-Moreno JM, Arias L, Montero JA, et al. Intravitreal anti-VEGF therapy for choroidal neovascularisation secondary to pathological myopia: 4-year outcome[J]. Br J Ophthalmol, 2013, 97(11): 1447-1450. DOI: 10.1136/bjophthalmol-2012-302973.
|
33. |
Ikuno Y, Sayanagi K, Soga K, et al. Intravitreal bevacizumab for choroidal neovascularization attributable to pathological myopia: one-year results[J]. Am J Ophthalmol, 2009, 147(1): 94-100. DOI: 10.1016/j.ajo.2008.07.017.
|
34. |
Mones JM, Amselem L, Serrano A, et al. Intravitreal ranibizumab for choroidal neovascularization secondary to pathologic myopia: 12-month results[J]. Eye (Lond), 2009, 23(6): 1275-1280. doi: 10.1038/eye.2009.88.
|
35. |
Ikuno Y, Ohno-Matsui K, Wong TY, et al. intravitreal aflibercept injection in patients with myopic choroidal neovascularization: the MYRROR study[J]. Ophthalmology, 2015, 122(6): 1220-1227. DOI: 10.1016/j.ophtha.2015.01.025.
|
36. |
Inhoffen W, Ziemssen F. Morphological features of myopic choroidal neovascularization: differences to neovascular age-related macular degeneration[J]. Ophthalmologe, 2012, 109(8): 749-757. DOI: 10.1007/s00347-011-2498-3.
|
37. |
Gharbiya M, Allievi F, Mazzeo L, et al. Intravitreal bevacizumab treatment for choroidal neovascularization in pathologic myopia: 12-month results[J]. Am J Ophthalmol, 2009, 147(1): 84-93. DOI: 10.1016/j.ajo.2008.07.022.
|
38. |
Niwa Y, Sawada O, Miyake T, et al. Comparison between one injection and three monthly injections of intravitreal bevacizumab for myopic choroidal neovascularization[J]. Ophthalmic Res, 2012, 47(3): 135-140. DOI: 10.1159/000330499.
|
39. |
Ruiz-Moreno JM, Montero JA, Arias L, et al. Three versus one intravitreal bevacizumab injections as initial protocol to treat myopic choroidal neovascularization[J]. Acta Ophthalmol, 2012, 90(1): 82-83. DOI: 10.1111/j.1755-3768.2010.02070.x.
|
40. |
Wakabayashi T, Ikuno Y, Gomi F.Different dosing of intravitreal bevacizumab for choroidal neovascularization because of pathologic myopia[J]. Retina, 2011, 31(5): 880-886. DOI: 10.1097/IAE.0b013e3181f2a293.
|
41. |
Fung AE, Lalwani GA, Rosenfeld PJ, et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration[J]. Am J Ophthalmol, 2007, 143(4): 566-583. DOI: 10.1016/j.ajo.2007.01.028.
|
42. |
Wang S, Peng Q, Zhao P. SD-OCT use in myopic retinoschisis pre- and post-vitrectomy[J]. Optom Vis Sci , 2012, 89(5): 678-683. DOI: 10.1097/OPX.0b013e31824eeaed.
|
43. |
Introini U, Casalino G, Querques G, et al. Spectral-domain OCT in anti-VEGF treatment of myopic choroidal neovascularization[J]. Eye (Lond) , 2012, 26(7): 976-982. DOI: 10.1038/eye.2012.75.
|